Folic acid

Catalog No.S4605 Batch:S460501

Print

Technical Data

Formula

C19H19N7O6

Molecular Weight 441.40 CAS No. 59-30-3
Solubility (25°C)* In vitro DMSO 2 mg/mL (4.53 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Folic acid (Folacin, Vitamin B9, Vitamin M, Pteroylglutamic acid, Folate), a B vitamin, plays an important role in cell division and in the synthesis of amino acids and nucleic acids like DNA.
In vitro Folic acid treatment induces dose-related increases in BRCA1 mRNA expression in HepG2, Huh-7D12, Hs578T, and JURKAT and in BRCA2 in HepG2, Hs578T, MCF7, and MDA-MB-157 cells. FA does not affect the corresponding normal cells or on any of the ovarian cell lines. Folic acid induces increased BRCA1 protein expression in Hs578T, but not HepG2 cells, whereas BRCA2 protein levels are undetectable. FA treatment does not alter DNA repair in liver-derived cells, whereas there are transient effects on breast-derived cells. There is no effect of FA treatment on BRCA1 or BRCA2 DNA methylation, although there is some variation in the methylation of specific CpG loci between some cell lines[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    HepG2, Huh-7D12, Hs578T, JURKAT, Hs578T, MCF7, and MDA-MB-157 cells

  • Concentrations

    0, 25, 50, 75, or 100 nmol/L

  • Incubation Time

    72 h

  • Method

    To determine the effect of FA supplementation on BRCA1 and BRCA2 mRNA expression, all cell lines were treated with 0, 25, 50, 75, or 100 nmol/L FA for 72 hours before harvesting in TRI Reagent according to the manufacturer’s instructions.

Animal Study:

[2]

  • Animal Models

    ICR strain mice

  • Dosages

    3 mg/kg

  • Administration

    by gastric intubation

Selleck's Folic acid has been cited by 3 publications

HDAC3 aberration-incurred GPX4 suppression drives renal ferroptosis and AKI-CKD progression [ Redox Biol, 2023, 10.1016/j.redox.2023.102939] PubMed: 37890360
Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension [ Oxid Med Cell Longev, 2022, 2022:1486157] PubMed: 36046692
Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein [ J Mol Model, 2022, 28(6):153] PubMed: 35578055

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.